Eur Respir Rev. 2012 Sep 1;21(125):234-238.

The study of risk in pulmonary arterial hypertension.

Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S.

School of Medicine, University of California San Diego, La Jolla, CA
University of Colorado Health Sciences Center, Denver, CO
School of Public Health, Boston University, Boston, MA,
Dept of Ophthalmology, Washington University School of Medicine, St Louis, MO, USA.
Service de Pneumologie, University of South Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Dept of Cardiology, University of Bologna, Bologna,
Dept of Biomedicine, Division of Rheumatology, AOUC,
Dept of Medicine, Denothe centre, University of Florence, Florence, Italy.
Heart and Lung Transplant Unit, St Vincent's Public Hospital, Sydney, Australia.

Abstract

A growing body of published evidence exists on the risk factors for disease progression in pulmonary arterial hypertension (PAH). The Scientific Steering Committee for the Study of Risk in PAH was established to bring together leading clinical and statistical experts in PAH and risk modelling, for the purpose of advancing the understanding of the risk of development and progression of PAH. Herein, we discuss the impact of this information on three key areas: 1) clinical decision-making; 2) policy and reimbursement; and 3) future trials and research.

PMID:22941888